Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.64
+0.03 (0.45%)
Mar 12, 2025, 1:37 PM EST - Market open
Solid Biosciences Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Solid Biosciences stock have an average target of 18.17, with a low estimate of 12 and a high estimate of 40. The average target predicts an increase of 222.45% from the current stock price of 5.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Solid Biosciences stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 3 | 4 | 4 | 4 |
| Buy | 7 | 6 | 8 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $20 | Strong Buy | Maintains | $16 → $20 | +254.92% | Mar 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +183.94% | Mar 7, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $15 | Buy | Reiterates | $15 | +166.19% | Mar 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 → $16 | Strong Buy | Maintains | $15 → $16 | +183.94% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +183.94% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
255.00K
Revenue Next Year
2.09M
from 255.00K
Increased by 717.65%
EPS This Year
-2.78
from -3.06
EPS Next Year
-2.77
from -2.78
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2M | 19.3M | 47.7M | ||
| Avg | 255,000 | 2.1M | 15.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 7,476.5% | 2,186.3% | ||
| Avg | - | 717.6% | 640.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.50 | -1.66 | -2.33 | ||
| Avg | -2.78 | -2.77 | -2.33 | ||
| Low | -3.42 | -4.51 | -2.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.